Quotient Biodiagnostics Raises Further $5.0 Million of Growth Finance Led by Paul Cowan and Galen Partners

Quotient Biodiagnostics Holdings
Specialty Pharmaceuticals

Update: Tuesday, 26 February 2013

EDINBURGH, Scotland & NEWTOWN, Pa.

Quotient Biodiagnostics (“Quotient”), a global transfusion diagnostics group, is pleased to announce that its shareholders have invested a further $5.0 million in the company.  Over the past 18 months Quotient has raised over $19 million of new equity.

The company will use the new equity to continue development of its next generation automation platform for transfusion diagnostics.  In connection with this, Quotient is pleased to announce the appointment of Ed Farrell as the corporate President responsible for this project.  Ed joins Quotient from Siemens Healthcare Diagnostics.

Quotient is also continuing to pursue its plans to build a new facility to facilitate the expansion of its existing liquid reagent business in Scotland.

“Following the initial Galen investment in February 2012, the group has made significant advances. I am also pleased to welcome Ed Farrell on board at this key point in the next stage on the Company’s development” said Paul Cowan, Chief Executive and Founding Shareholder of Quotient. “Key business areas have experienced revenue growth exceeding 50% compared with the prior year.  Additionally, major progress has been made towards the development of the group’s next generation automation platform for blood typing, both internally and externally. With the appointment of Ed Farrell we look forward to advancing this project to commercial launch over the next few years.”

“We are pleased to invest further growth equity in Quotient” said David Azad, Managing Director of Galen Partners. “Paul and his team, in Scotland and the US, have achieved what they said they would achieve in delivering high quality, innovative products to transfusion professionals worldwide. We are excited about the direction of the company.”

About Quotient Biodiagnostics
With a proven record over the past 30 years, Quotient is a trusted leader in transfusion diagnostics. The group serves major transfusion diagnostic companies as an innovative product development and supply chain partner.  Additionally Quotient serves the blood banking and transfusion medicine community through the direct provision of high quality transfusion diagnostic products.  It is also developing a next generation automation platform for the transfusion diagnostics market, offering the ability to make better-informed clinical decisions whilst delivering major benefits over existing laboratory practices.
Based in the USA, Quotient Biodiagnostics, Inc. (the group’s North American sales and marketing business) provides the US blood banking community with trusted transfusion diagnostics products manufactured over many years outside of the US.  For more details about the full range of products offered by Quotient in the United States of America, please visit our website, www.quotientbd.com.

Alba Bioscience is the product development and manufacturing arm of Quotient.  It has a distinguished record of developing and manufacturing innovative transfusion diagnostics for Quotient and other major transfusion diagnostics groups worldwide.  For more details about the full range of products offered by Alba Bioscience and Quotient outside of the USA, please visit our website, www.albabioscience.co.uk.

About Galen Partners
Galen Partners is a leading healthcare venture capital investment firm.  The firm focuses on growth equity investments in healthcare technology and services, medical products, and specialty pharmaceutical companies.  With nearly $1 billion under management, raised through five funds, Galen has helped build more than 70 companies since our founding in 1990.  The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams to build healthcare market leaders.  For more information, please visit Galen’s web site atwww.galen.com.
 
Contact:
Quotient Biodiagnostics Holdings Limited
Paul Cowan, +44 131-536-5907
Chairman & Chief Executive Officer
or
Jeremy Stackawitz, +1 215-497-8820
President

® 2016 Galen Partners, All Rights Reserved

Galen Partners and International Business Forum Announce Details for Inaugural Healthcare Growth Capital Conference

Galen
Latest News

 Update: Friday, 08 February 2013

Healthcare Growth Capital Conference will be held on April 11, 2013, at the W Hotel in New York City. The conference is being co-sponsored by Galen Partners, a leading growth equity firm focused solely on the healthcare industry, and International Business Forum, a world-class media and event production company.

The conference is designed as a forum for the exchange of strategies on growing existing healthcare businesses to scale and providing expansion capital to high-growth companies with revenues of ten million to hundreds of millions of dollars. Conference attendees will include CEOs and senior managers of high-growth healthcare companies, corporate business development executives and private equity investors.

“Growth capital investing in the healthcare sector has driven industry transformation, while providing investors with superior returns,” said Conference Chairman and Galen Managing Partner, Zubeen Shroff, who has over twenty years of experience in building healthcare companies.  “Galen’s well-established track record of leading healthcare growth investments made us a natural partner to work with International Business Forum in developing what we expect to be a powerful forum for uniting key industry participants.”

Mr. Shroff is supported in the development of this high caliber program by an accomplished Board of Advisors which includes:

Jeff Crisan
Managing Director, Bain Capital Ventures

Adam Dolder
Managing Director, Great Point Partners

Tom Flynn
Partner, SV Life Sciences

Bill Geary
Partner, North Bridge

Patrick Heron
General Partner, Frazier Healthcare

Daniel Killeen
Associate, Goldman Sachs Merchant Banking

Mike Kluger
Managing Director, Altaris

Aaron Lillybridge
Principal, Baird Capital

David Mayer
Partner, Abingworth

Adele Oliva
Partner, Quaker Partners

Matt Rizzo
Managing Director, OrbiMed

Michael Wasserman
Managing Director, H.I.G. BioVentures

Key themes to be addressed at the inaugural meeting include: Defining the boundaries of success for growth investing; how chaos in Washington will affect healthcare companies and create investment opportunities; building service platforms of scale for the new healthcare economy; the evolution of specialty pharma and diagnostics; maximizing milestone and escrow collection post-transaction; cultivating rapid growth for emerging medical device companies; non-dilutive financing strategies for growth stage companies; digitizing the American healthcare system; and risk adjustment and assessment in the payor universe.

For more information on this unique event and to sign up to participate, visitwww.growthcapcon.com.

Contacts
International Business Forum
Craig Simak
Chief Strategy Officer
craig@ibfconferences.com 

NICHD Experts Validate EFM Analysis by PeriCALM Patterns

Software can be used to screen in real-time when an expert is not present.


PeriGen, Inc.
Information Technology & Services

 Update: Tuesday, 15 January 2013

Princeton, NJ, January 15, 2013 – PeriGen, Inc., the global leader in applying real-time clinical decision support to perinatal systems, today announced the results of an independent validation study on fetal strip interpretation favorably comparing PeriGen PeriCALM® Patterns software with the findings of three experts from the National Institute of Health (NIH).  The FDA-cleared fetal strip interpretation technology is a component of the company’s perinatal central surveillance offering.

The study reviewed the analysis of PeriCALM Patterns during the final hour of 100 tracings, and concluded that, “computerized fetal heart rate interpretation has substantial agreement with experts’ evaluation. The software can be used to efficiently evaluate stored fetal heart rate data retrospectively as well as to screen in real time when an expert is not continuously evaluating the fetal heart rate,” as reported by Steven Wiener of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal-Fetal Medicine Units Network, Bethesda, Maryland.  In over 97 percent of the assessments, the experts agreed withthe analysis by PeriCALM Patterns. 

This validation study is the first phase of a research collaboration announced earlier in 2012, Computerized Interpretation of Intrapartum FHR and Prediction of Neonatal Outcomes, with primary investigators George R. Saade, MD, University of Texas Medical Branch in Galveston, Texas, and Sean Blackwell, MD, University of Texas at Houston-Children’s Memorial Hermann Hospital.  The findings will be presented at the Annual Clinical Meeting of the Society of Maternal Fetal Medicine (SMFM) in San Francisco on February 16, 2013 and were published in the American Journal of Obstetrics and Gynecology, Vol. 208, Issue 1, Supplement S316-S317.

“We are delighted by the results,” commented Dr. Emily Hamilton, Senior Vice President of Clinical Research, PeriGen. “Internationally recognized experts participated in this extensive and completely independent test. These results demonstrate that clinicians can have confidence in the use of PeriCALM at the bedside. In addition, other researchers can rely upon the software to consistently analyze thousands of tracings retrospectively and test new scientific hypotheses to clarify what combination of FHR features are truly indicative of impending birth related hypoxic injury.”

“PeriCALM Patterns from PeriGen provides far more clinical insight than other central perinatal surveillance systems into what is arguably the most subjective and highest risk task in delivering a baby – interpreting the fetal monitoring strip,” said PeriGen CEO Matthew Sappern.  “The incremental insight provided by PeriCALM Patterns means better information for making clinical decisions and promoting improved outcomes.”

About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
The NICHD sponsors research on development before and after birth; maternal, child and family health; reproductive biology and population issues; and medical rehabilitation. For more information, visit the Institute’s website atwww.nichd.nih.gov.

About the Society of Maternal Fetal Medicine (SMFM).
The SMFM is a Society of physicians and scientists who are dedicated to the optimization of pregnancy and perinatal outcomes. Their mission is twofold: improving maternal and child outcomes and raising the standards of prevention, diagnosis and treatment of maternal and fetal disease through support for the clinical practice of maternal-fetal medicine, research, education/training, advocacy and health policy leadership. For more information, visit www.smfm.org.

About PeriGen, Inc.
PeriGen. Inc., is an innovative provider of fetal surveillance systems employing patented, pattern-recognition and obstetrics technologies that empower perinatal clinicians to make confident, real-time decisions about the mothers and babies in their care. PeriGen’s customer-centric team of clinicians and technologists builds the most advanced systems available to augment obstetric decision-making and improve communications among the clinical team at the point of care, while supporting data flow between healthcare IT systems.

PeriGen’s unique fetal surveillance products provide dynamic visual cues that direct clinicians to the most essential patient information displayed on the screen. Unlike legacy fetal monitoring devices and software from non-specialist companies, PeriGen Visual Cueing™ provides an instant view of the mother’s and baby’s current status and trends over time to avoid errors, increasing patient safety and reducing risk for clinicians and hospitals. For more information, please visit us atwww.PeriGen.com.

Isabelle Lafortune
PeriGen
(514) 488-3461 ext.237
Isabelle.lafortune@perigen.com

Tactile Systems Technology Appoints New Board Chair, Expands Medical Leadership

Industry thought leaders add momentum to company’s growth plans

Tactile Systems Technology Inc.
Medical Devices & Technology

 Update: Thursday, 03 January 2013

FOR IMMEDIATE RELEASE

Minneapolis – Jan. 3, 2013 – Tactile Systems Technology Inc., a Minneapolis-based developer of chronic swelling and vascular disease therapies, is adding veteran leadership and top medical talent as it prepares to enter new markets and broaden its treatment portfolio. The appointments include a new chairman of the board of directors, a scientific advisory board and a chief medical officer.

“Attracting this level of business and clinical experience prepares us to accelerate our growth in new markets,” said Jerry Mattys, CEO of Tactile Systems Technology. “Having the full support of these key industry thought leaders speaks to the potential of our products. Tactile will leverage their expertise for its expansion plan in 2013.”

Chairman of the Board
Seasoned med-tech business leader Peter H. Soderberg has been elected by the company’s board of directors to serve as its chairman. As former President & CEO of medical device manufacturers Hill Rom and Welch Allyn, Soderberg will provide strategic direction as Tactile Systems Technology plans to expand existing and develop new products and markets for treatment of chronic swelling.

“Tactile continues to hone its therapies and develop products that dramatically impact patients’ well-being,” Soderberg said. “I’m excited to work with the company to help them advance the standard of care in treating chronic diseases at home.”

Scientific Advisory Board
Tactile has formed a new scientific advisory board to strengthen the company’s clinical development strategic direction and oversight.  The scientific advisory board consists of top international medical experts and will assist the company in planning, designing and implementing clinical trials. In addition, the board’s research will fuel further therapy exploration. The advisory board includes:

  • Thomas F. O’Donnell, Jr., MD (panel chairman): Senior vascular surgeon at Tufts New England and the Benjamin Andrews Professor of Surgery Emeritus at Tufts University School of Medicine.
  • Hugo Partsch, MD: Professor Emeritus of Dermatology at University of Vienna, Past - President of the International Union of Phlebology and founder, International Compression Club.
  • Anthony J. Comerota, MD: Director of the Jobst Vascular Institute at The Toledo Hospital in Toledo, Ohio, and adjunct professor of surgery at the University of Michigan.
  • Steven M. Dean, DO: Director of the vascular medicine program, director of cardiovascular medicine’s noninvasive peripheral vascular laboratory and associate professor of clinical medicine at The Ohio State University Medical Center.

Chief Medical Officer
Alan T. Hirsch, MD, will serve as Tactile’s new chief medical officer, overseeing protocol design, safety reviews of new therapies and clinical education programs. He is Professor of Medicine and the current director of the University of Minnesota Medical School’s vascular medicine program.

About Tactile Systems Technology Inc.  
Tactile Systems Technology Inc., headquartered in Minneapolis, is a medical device company dedicated to advancing the standard of care for the at-home treatment of chronic diseases. The company’s Flexitouch® system is a programmable pneumatic compression device designed to help patients with edema and vascular disease improve their overall health and enjoy a higher quality of life. As a leader in lymphedema treatment, and serving tens of thousands of patients throughout the U.S., the mission of Tactile Systems is to establish Flexitouch® system as a standard in the treatment and care of lymphedema and chronic wound patients at home. Galen Partners of Stamford, CT, Radius Ventures of New York, NY and individual investors (including board chairman Peter Soderberg) have provided funding to Tactile Systems. Visit www.tactilesystems.com for more information.

Contacts:

Tactile Systems Technology: Jerry Mattys, CEO, (612) 355-5100, jmattys@tactilesystems.com

Padilla Speer Beardsley: Janet Stacey, (612) 455-1760, jstacey@padillaspeer.com

Galen's Growth-Equity Approach Pays Off Through National Rehab and Aperio Exits

Aperio Technologies, Inc. 
Medical Devices & Technology

 Update: Friday, 26 October 2012
By Brian Gormley

Galen Partners, which infuses small but growing health-care businesses with expansion capital, has recently sold its stake in medical-product supplier National Rehab Equipment Inc. to an undisclosed buyer, the firm told VentureWire.

Galen, formed in 1990, typically provides the first institutional capital to companies whose growth can outpace that of their market, said Managing Partner Zubeen Shroff. After investing, the firm works with management and existing shareholders to put the company on a path to achieve that expansion. The firm's approach has also paid off recently through the sale of digital-pathology company Aperio Technologies Inc., which has just merged with Leica Biosystems.

The Stamford, Conn., firm invested in National Rehab in 2007. A family-founded business, National Rehab was looking to expand from a local player to a regional and national one, Mr. Shroff said. The company, which has offices in Moon Township, Pa., supplies medical products directly to consumers. These include supplies used in wound care and to manage conditions such as incontinence and urological problems.

While the competition was growing at about 5% a year, National Rehab grew at a rate that was several-fold faster, largely because of its focus on customer service, which is paramount in this direct-to-consumer business, according to Mr. Shroff. He said he couldn't discuss specifics about the sale of Galen's stake, such as the amount it invested, the sale price, and the buyer, but said the firm is pleased with the outcome. A National Rehab representative wasn't available for comment.

Aperio, which says it has advanced the technology that enables glass slides to be digitized and securely shared, was smaller than National Rehab when Galen made its original investment, in 2005, Mr. Shroff said. Aperio, which had sales in the low single-digit millions at the time, applied its technology to the pharmaceutical research-and-development market.

After raising capital from Galen and Advanced Technology Ventures that year, it expanded into the hospital market, where digital pathology could enable easier sharing of information among pathologists. Mr. Shroff declined to discuss the amount invested in the company, but VentureWire records show that Aperio raised a $17 million Series B financing in 2005 co-led by Galen and ATV.

Aperio, based in Vista, Calif., had excellent intellectual property and a well-developed system for the drug-research market, Mr. Shroff said. But for clinical care, it needed simpler interfaces and features and benefits that were more appropriate for a hospital setting. The company did marketing studies to find out what clinical customers found to be most important, changed configurations for its devices and made the interface more clinically friendly, according to Mr. Shroff.

Aperio established itself in this market by selling to large hospitals in the U.S. and Europe, he said. Aperio, whose product line includes scanners, image-management software, and image-analysis tools and services, has grown significantly from where it was in 2005, according to Mr. Shroff, but he didn't give specifics. Terms of the company's sale weren't disclosed.

Other Aperio backers included HLM Venture Partners, which led a $20 million Series C round in 2008 that also included new investor Acadia Woods Partners and BlackRock Alternative Advisors, according to VentureWire records.

Aperio's biggest challenge was establishing the market for its services, Mr. Shroff said.

"Today, everybody knows that digital pathology is important," he said. "It wasn't as obvious in 2005."

http://www.galen.com

Write to Brian Gormley at brian.gormley@dowjones.com

Leica Biosystems Completes Acquisition of Aperio, a Galen Partners Portfolio Company

Aperio Technologies, Inc. 
Medical Devices & Technology

 Update: Wednesday, 24 October 2012

Galen Partners, a leading healthcare growth equity investment firm, announced today that an affiliate of Leica Bioysystems has completed its acquisition of Aperio, a leading provider of ePathology solutions. Aperio will be integrated into Leica Biosystems, a leader in anatomical pathology solutions. Together, the two businesses will leverage each other’s strengths to grow and expand digital pathology into the global Life Science and Healthcare markets. The integrated business will provide industry leading solutions in each step of the anatomical pathology workflow, from sample preparation and staining, to imaging and reporting. The company will continue to offer both the Aperio ePathology Solutions and the existing Leica portfolio of Digital Pathology solutions, so that customers will enjoy more freedom to choose a solution that meets their individual needs.

Galen Partners first partnered with Aperio in 2005. Over the next seven years, Aperio solidified its reputation as a global leader in digital pathology while maintaining and expanding the largest installed base of digital pathology systems in the world. “For over 20 years, Galen has partnered with driven management teams to build sustainable healthcare businesses,” said Zubeen Shroff, Managing Partner of Galen Partners. “We commend Aperio’s successful execution of building a leading digital pathology platform. We are proud of Aperio’s accomplishments and want to acknowledge the vision of Dirk Soenksen and the leadership of David Schlotterbeck and his team in successfully commercializing this technology globally over the past seven years. We are pleased this pioneering platform will be part of Leica’s anatomical pathology solutions.”

“We believe that Aperio will benefit from the heritage, deep pathology expertise, and strong brand recognition of Leica Biosystems,” said David Schlotterbeck, CEO of Aperio. “The combined product offerings and improved reach into the diagnostic market will make our ePathology Solutions more widely available. We see our goals as synergistic and together we can address the regional and global imbalances of pathology expertise available for patient care and research.”

About Aperio
For over a decade, Aperio has advanced the technology that enables glass slides to be digitized and securely shared with others. Aperio products are transforming the practice of pathology in hospitals, reference labs, and pharmaceutical and research institutions around the world. From the moment glass slides are elevated to eSlides, Aperio ePathology Solutions equip pathologists with the power to evaluate, engage, and excel like never before. The NETWORK enables remote, simultaneous, real-time viewing and easy distribution for consults and collaboration. PRECISION tools empower pathologists with advanced analytic capabilities. An interoperable, scalable, and secure web-based software platform facilitates integration with existing systems. With Aperio ePathology Solutions, organizations can optimize their pathology operations for transparency, consistency, and efficiency to support patient care, personalized medicine, and research. For clearance updates, specific product indications, and more information, please visit www.aperio.com.

About Galen Partners
Galen Partners is a leading healthcare venture capital investment firm. The firm focuses on growth equity investments in healthcare technology and services, medical products, and specialty pharmaceutical companies. With nearly $1.0 billion under management, raised through five funds, Galen has helped build more than 70 companies since its founding in 1990. The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams to build healthcare market leaders. For more information, please visit Galen’s web site atwww.galen.com.

Contact:

Zubeen Shroff, Managing Partner
Galen Partners
203-653-6400

HIStalk Interviews Matt Sappern, CEO, PeriGen

PeriGen, Inc.
Information Technology & Services

Update: Wednesday, 19 September 2012

Matthew Sappern is CEO of PeriGen of Princeton, NJ

Tell me about yourself and the company.

I joined PeriGen in January of this year. I came over from Allscripts and Eclipsys, where I had been for about eight years in various capacities. I headed up a big chunk of our development organization at one time, ran our remote hosting business, ran our services business for a while, and then after the merger, ran all of our client sales for a year-plus. I joined PeriGen in January, and now I am getting my arms around labor and delivery.

What is the size and scope of the company?

We are about 100 folks. We have offices in Tel Aviv, Princeton, and Montreal. We are the combination of two firms that merged in 2009. We have more than 150 customers right now, including Banner, MedStar, Maimonides, and Albert Einstein. It is a good cross-section of teaching hospitals as well as community hospitals. Our solution flexes pretty well across the entire gamut of hospitals.

How have fetal surveillance systems changed the way that obstetricians had practiced over the years?

The interesting part about fetal surveillance systems is that they really have not changed much at all for a number of years. That is what attracted me to PeriGen. It was the first time that I saw that any vendor was applying some new technology and starting to innovate.

Surveillance systems, archiving, and annotation on the strip have been around a long time. Everybody does it, right? Philips, OBIX, GE, WatchChild, and PeriGen… we all do it pretty well, to be honest with you. PeriGen takes a different approach in applying evidence-based medicine to detect when there is risk in labor. I am hoping that we are ushering in a whole new age of applying systems to healthcare. That is really what drove me here.

That must be a different driver than at Allscripts, where you had to convince doctors to use CPOE or EMRs because someone else wanted them to even though the benefit might not necessarily accrue to them personally. I assume obstetricians want or demand PeriGen’s products?

When I was at Allscripts, Meaningful Use happened and hospitals were getting behind EMRs. It is a great feeling when we show our product. Clinicians’ eyes really light up, because it is just a bit different from everything else that is out there.

It does everything that what I term “commodity systems” need to do, but our ability to apply technology to what has been a subjective part of labor and delivery is important. Probably 80% of medical malpractice comes back to bad interpretation of the fetal monitoring strip. We have figured out a way to apply technology to help interpret that strip.

Doctors and nurses … their eyes tend to light up when they see this stuff. I think as with every new disruptive technology, it takes a little bit of time for people to understand why it is so much better than what is out there, particularly as budgets are tight.

What malpractice benefits have obstetricians seen from using the product?

There is a bunch. Banner Health Systems has seen a precipitous drop, on the order of millions, in their malpractice expense.

Not only are we a great hedge on the downside of malpractice, but it is my contention that we actually can help hospitals categorize when there are complications with labor, and potentially get greater reimbursement for that work. Even Medicaid provides higher reimbursement for vaginal delivery with complications as opposed to vaginal delivery without, but a lot of times that goes unchecked because there is no simple system to categorically and systematically define or determine whether there have been complications in labor. 

Most of the physician documentation begins with the moment of birth. Our ability to show that there were complications in the labor portion, we think, is going to allow hospitals to correctly charge and code their DRGs and establish some top-line revenue growth as well.

As unfortunate as it is when there is any kind of patient harm that could have been avoided, everybody is very sensitive to anything involving newborns or peds. When you look at those malpractice-driven events, are they usually because of lack of following procedures or failure to detect complications?

Those go hand in hand sometimes. A lot of times there is a subjective interpretation around whether the fetal monitoring strip is showing complications or not. What we have tried to do is firmly establish a tool that helps us determine that case. In fact, the NIH has licensed our tool to go back and take a retrospective view of thousands of strips from problematic births to determine if there is any way to change the protocol. 

Many companies are trying to develop software to analyze incoming data streams from patient monitoring systems. What have you learned as an early adopter in applying evidence to physiologic monitoring data?

You are only as good as the evidence. We have put an awful lot of research into the 19 patents that we have. We have about 6,500 OB-specific protocols that we use. We are continuously vetting that.

We have got some great clients. They work very closely with us in helping to shape our product as we go forward. Sometimes they say, “This protocol might be a little bit outdated”, or “We had a case in here that your system really doesn’t contend with, and here’s how we think the workflow ought to go”, and they help write new protocols. I think vigilance is part of that.

You are applying accepted knowledge, but it sounds as though you are also using the information you collect to develop what may become the next standard?

Yes. Standards evolve. Part of evidence-based medicine is when you get the evidence of something evolving; you got to take advantage of it. We are constantly working with our clients to evolve our solution set. It has really worked out well for us and for them.

Everybody is spending a lot of their time and money working to implement electronic medical records, but the solutions market seems solid for high-acuity specialty areas like surgery, labor and delivery, and the ICU. Is it hard to earn a place at the table when those hospitals have made their big investments, and you are offering them a system they may not have thought about?

I think the rush towards Meaningful Use and deploying EMRs in as fast a manner as possible definitely eats up resources on the hospital side that they would otherwise deploy against programs like ours. But I think you are absolutely right that there are specific areas in the hospital and labor and delivery, where perinatal is probably the highest-risk service line in most hospitals. There is just so much nuance that I do not think any of the larger EMRs can develop. I would like to think that most of the clinicians understand the need for a specialty solution like ours.

You mentioned that your competitors do a good job. How do you differentiate PeriGen from them?

We are the only ones who have gone well beyond that commodity solution set of surveillance, annotation, and archiving. To us, that is great, but it is an old application of technology. We are truly the only ones who are certainly doing that, but also applying our systems to deliver clinical decision support, to essentially say, “Hey, doc or hey, nurse — you’ve got a problem here. You need to look at this” and allow that clinician to intervene.

None of the other systems do that. In a way, I do not feel like we have any competition because no other systems are doing that. Everybody is doing the commodity stuff. Nobody is doing what we do.

Where do you take it from here? Companies usually branch out into something unrelated or add functionality to what they have.

There are a number of different directions. If you look at the number of obstetricians that are going through school, you see a downward trend in terms of available obstetrical talent. Careers are running a little bit shorter. It is hard work being an OB, getting up in the middle of the night all the time.

Our solution set lends itself to a service line around the remote OB hospitalist, an intriguing direction that we’re looking at. There is a number of areas that our technology is well suited for because it is so visual and it’s doing a lot of the heavy lifting for the clinician. I think we are far more suited for that kind of a solution set than anyone else in the space.

At the heart of it though, we also have an engine that can be abstracted away from labor and delivery content and populated with content from other departments as well. The concept of applying clinical decision support engines at the bedside in real or near-real time is one that can grow pretty significantly into other service lines.

I had not heard of remote OB hospitalists. How is your product used remotely compared to products like AirStrip?

We are published via Citrix. There are a number of physicians using mobile applications now without using AirStrip. The last time I was at Banner, I was speaking to a doctor, and he was sitting there on his iPad looking at tracings and actually entering some orders. Mobility is something that we feel pretty confident that there is a solution set around for us and that a lot of our clients are already employing our solution in a mobile fashion.

The remote OB is a different concept. If you are in a hospital somewhere where you are having trouble getting access to OBs, like any number of community hospitals around the country, perhaps there is a service that provides a consulting physician or that uses our system as an alerting system, like an ADP in home security.

None of these are productized now, but your question was where our application goes. Our application allows immediate visual recognition of a problem, so therefore lends itself to a number of services that do not exist today.

In a small town, obstetricians spend a lot of time waiting on labor to progress. Is it easier for hospitals to attract and use those obstetricians efficiently when they have a tool like yours?

Yes. There is no doubt that both nurses and doctors have a more efficient workflow when they are using our tools. Nurses can come in, check on patterns, and see it right away over a two-hour trend line whether there are problematic decelerations or not in the labor. It is a lot more relevant clinical information and a lot quicker than having to stare at the strip or unroll the strip out on the bed and see what’s going on.

How do you think obstetric services and obstetricians will fare under the Affordable Care Act?

I am more worried about the number of obstetricians, frankly. I think they are going to be fine. As you look at where hospitals are going with accountable care organizations, I think tools like ours are going to become more and more important. 
If there is a baby that is born with a birth defect – heaven forbid, but we all know it happens — that child is in that system for, in many cases, the perpetuity of its life. Any tool like ours that employs systems to manage risk is going to be quite important in accountable care organizations going forward.

Ultimately, I think that the practice of obstetrics is changing. We are going to continue to see a higher demand, as there are less OBs delivering babies. Systems like ours can help make those OBs and the nurses on staff a bit more productive, which is what we see a lot of excitement around.

From your time at Allscripts, what lessons did you learn that you will and will not apply at PeriGen?

There are a lot of things that we can do, being a much smaller organization than Allscripts and having a much tighter focus. We have got the freedom, agility, and speed to do things that they maybe cannot do quite as well. There are organizational tenets that I am taking a slightly different approach than we ever did at Allscripts relative to how I am organizing our development and product teams. Stuff that the size and scope of Allscripts just wouldn’t allow.

Any concluding thoughts?

When I saw this application at work, I had been up for the job and I was not sure if I was going to take it. I wanted to go see the application at work in one of our client hospitals. There was a woman having some complications and decelerations in labor, which are bad. I am not a doctor, so that is about as medical as I am going to get.

Our system helped detect what was going on. They were able to do an emergency C-section. Everything came out great. At that point, I saw more than ever in my career how technology can change the course of healthcare on a patient-by-patient basis.

I feel like we are bringing innovation where there has been little to date. We are applying technology to one of the most problematic and subjective areas, which is interpreting the fetal monitoring strip. It is a great proving ground for clinical decision support overall.

Fetal Surveillance Company, PeriGen, Inc., to Collaborate with National Institute of Child Health and Human Development to Research Fetal Heart Rate Patterns During Labor

PeriGen, Inc.
Information Technology & Services

Update: Tuesday, 14 August 2012

PRINCETON, N.J., PeriGen, Inc., and The George Washington University, the data coordinating center of the Eunice Kennedy Shriver National Institute of Child Health and Human Development's Maternal-Fetal Medicine Units Network, have entered into an agreement to utilize PeriGen's PeriCALM® Patterns™ software in connection with a research project entitled: Computerized Interpretation of Intrapartum FHR and Prediction of Neonatal Outcomes. The primary investigators are George R. Saade, MD, University of Texas Medical Branch in Galveston, Texas and Sean Blackwell, MD, University of Texas at Houston-Children's Memorial Hermann Hospital.

The Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD) started the Maternal-Fetal Medicine Units (MFMU) Network in 1986 to focus on clinical questions in maternal-fetal medicine and obstetrics. The current Network is comprised of fourteen university-based clinical centers and a data coordinating center.  The primary investigators listed above have no financial interests with PeriGen.

PeriGen is a medical software company headquartered in Princeton, New Jersey, with offices in Canada and Israel. For more information, please visit us atwww.PeriGen.com.

Sandra Taylor, Ph.D.,

Chief Marketing Officer

PeriGen

(609) 228-8346

Sandra.Taylor@PeriGen.com

 

SOURCE PeriGen, Inc.

Dakim Clinical Trial Awarded Blue Ribbon by American Psychological Association

Efficacy of Dakim BrainFitness Confirmed in Clinical Trial

Dakim, Inc.
Information Technology & Services

Update: Tuesday, 07 August 2012

By Rick Sill

The results of Dakim’s clinical trial, conducted by researchers at UCLA, were presented at the American Psychological Association’s Annual Conference, August 3, 2012.

Co-author Karen Miller, PhD, associate clinical professor at the Semel Institute for Neuroscience and Human Behavior at UCLA, presented the findings from Dakim’s six month clinical, one of the first studies to analyze the affects on cognition in older adults using a computerized cognitive exercise program—Dakim BrainFitness! The study, noteworthy because of its potential impact on the science and practice of clinical neuropsychology, earned a Blue Ribbon Award from the APA.

The study found the intervention group who used Dakim BrainFitness showed significant improvement in memory and language skills. Furthermore, researchers proposed that brain fitness tools such as Dakim BrainFitness may help protect individuals from cognitive decline associated with aging and Alzheimer’s disease!

Contact
Rick Sill, Vice President of Sales:
888-693-2546 or rick@dakim.com

New Treatment For Prostate Cancer Gives 'Perfect Results' For Nine in Ten Men

SonaCare Medical
Medical Devices & Technology

 Update: Monday, 16 April 2012
By Rebecca Smith, Medical Editor

A new treatment for prostate cancer can rid the disease from nine in ten men without debilitating side effects, a study has found, leading to new hope for tens of thousands of men.

It is hoped the new treatment, which involves heating only the tumours with a highly focused ultrasound, will mean men can be treated without an overnight stay in hospital and avoiding the distressing side effects associated with current therapies. A study has found that focal HIFU, high-intensity focused ultrasound, provides the 'perfect' outcome of no major side effects and free of cancer 12 months after treatment, in nine out of ten cases.

Traditional surgery or radiotherapy can only provide the perfect outcome in half of cases currently. Experts have said the results are 'very encouraging' and were a 'paradigm' shift in treatment of the disease. It is hoped that large scale trials can now begin so the treatment could be offered routinely on the NHS within five years.

The National Institute for Health and Clinical Excellence will say in new guidance next week that the treatment is safe and effective and larger scale trials should go ahead. A larger trial is already recruiting patients and men interested in the treatment should speak to their cancer doctor or GP about being referrred, experts said.

Prostate cancer is the commonest cancer in men with more than 37,000 diagnoses each year approximately 10,000 deaths.  Current treatments include surgery to remove the whole prostate or radiotherapy. Both of which can effectively treat the cancer but often cause side effects such as incontinence and impotence.  However in many men prostate cancer will not progress to a life threatening disease meaning that radical treatment risks side effects unnecessarily. For this reason, research is now focused on reducing side effects.

Focal HIFU involves careful selection of tumours, as small as a grain of rice, within the prostate gland and targeting them with highly focused ultrasound to heat them and destroy them.

The advantage over previous HIFU and other treatments is that damage to surrounding tissue is minimised, meaning there are far fewer side effects.

In the study published in the journal Lancet Oncology, 41 men were treated with focal HIFU. After 12 months, none were incontinent and one in ten suffered impotence.

The majority, 95 per cent, were free of cancer after 12 months. Dr Hashim Ahmed, who led the study at University College London Hospitals NHS Foundation Trust and University College London said, “This changes the paradigm. By focusing just on the areas of cancer, we reduce the collateral damage to surrounding tissue".

"Our results are very encouraging. We’re optimistic that men diagnosed with prostate cancer may soon be able to undergo a day case surgical procedure, which can be safely repeated once or twice, to treat their condition with very few side-effects. That could mean a significant improvement in their quality of life. This study provides the proof-of-concept we need to develop a much larger trial to look at whether focal therapy is as effective as the current standard treatment in protecting the health of the men treated for prostate cancer in the medium and long term.”

He said after Nice guidance is issued next week, he expected other doctors to consider using the treatment.

He said, "These results will encourage more physicians to look at it more carefully.  If men are interested in this concept they should speak to their cancer doctror or their GP.  The next step is a large scale randomised controlled trial. This needs to be evaluated in a timly way so men can benefit".

The research programme is led by Professor Mark Emberton, of UCL and UCLH. He said, “Focal therapy offers harm reduction – it is a strategy that attempts to redress the balance of harms and benefits by offering men who place high utility on genito-urinary function an alternative to standard care.  In fact, the concept is not new - tissue preserving strategies have been used successfully in all other solid organ cancers such as breast cancer by offering women a lumpectomy rather than mastectomy".

Professor Gillies McKenna, Director of the Medical Research Council and Cancer Research UK Gray Institute for Radiation Oncology and Biology said, "Clinical trials, like this one supported by the MRC, are a fantastic tool for telling us whether experimental new treatments are likely to be effective in the clinic.  If these promising results can be confirmed in a randomized controlled trial, focal therapy could soon become a reasonable treatment choice for prostate cancer alongside other proven effective therapies".

The research was funded by the MRC, the Pelican Cancer Foundation and St Peter’s Trust.

Jacqui Graves, Interim Head of Healthcare at Macmillan Cancer Support said, “We welcome any research that shows early signs of improving the outcomes of treatment for prostate cancer patients. Significant reduction in the likelihood of common side effects, such as incontinence, will enable men to recover better and go on to lead good quality lives. We hope that a larger trial will be supported to ensure that the UK achieves the best outcomes for men affected by prostate cancer".

Owen Sharp, Chief Executive of The Prostate Cancer Charity said, “We welcome the development of any prostate cancer treatment, which limits the possibility of damaging side effects such as incontinence and impotence. These early results certainly indicate that focal HIFU has the potential to achieve this in the future. However, we need to remember that this treatment was given to fewer than 50 men, without follow up over a sustained period of time. We look forward to the results of further trials, which we hope will provide a clearer idea of whether this treatment can control cancer in the long term whilst ridding men of the fear that treating their cancer might mean losing their quality of life”.

Galen Partners Leads $11.2M Round for Quotient Biodiagnostics

Quotient Biodiagnostics Holdings
Specialty Pharmaceuticals

Update: Wednesday, 07 March 2012

PRESS RELEASE

Quotient Biodiagnostics Holdings has closed a $11.2 million growth equity financing round led by Galen Partners. David Azad and John Wilkerson from Galen Partners will join Quotient’s board as Non-Executive Directors. Quotient Biodiagnostics provides transfusion diagnostics.

Quotient Biodiagnostics Holdings Limited (“Quotient”), a global transfusion diagnostics Group, is pleased to announce that it has completed an $11.2 million growth equity financing led by Galen Partners, a US-based healthcare venture capital investment firm.

“Quotient is very pleased to introduce Galen Partners as a shareholder,” said Paul Cowan, Executive Chairman and Founding Shareholder. “In addition to new capital, Galen brings significant industry experience and a track record of building high growth companies. We look forward to building a long and successful relationship with them.”

The new funds will be used to fund the growth of the Quotient’s US commercial operations, to expand the Group’s manufacturing and product development operations in Edinburgh, Scotland and to accelerate the development of a next generation automated transfusion diagnostics platform.

As part of the fundraising, David Azad and John Wilkerson from Galen Partners will join the Board of Quotient as Non-Executive Directors. Additionally, Thomas A. Bologna (Chairman and CEO of Response Genetics) will also join the Board of Quotient as a Non-executive Director.

“With a tradition built over three decades, the Quotient companies have developed a distinctive global reputation as an innovator and trusted supplier of transfusion diagnostics. With Galen’s growth capital investment, Quotient will have transformative manufacturing and scientific resources to advance the field of transfusion diagnostics worldwide,” said David Azad, Managing Director of Galen Partners. “Galen is excited to partner with Paul and the teams in the USA and Scotland to accelerate growth and build an important company.”

About Quotient Biodiagnostics
Quotient Biodiagnostics, through its operating subsidiaries, is a trusted leader in transfusion diagnostics. The Group serves major transfusion diagnostic companies as an innovative product development and supply chain partner and the blood banking and transfusion medicine community through the direct provision of high quality transfusion diagnostic products proven over 30 years to ensure safe and reliable blood transfusions.

Based in Scotland, Alba Bioscience is the product development and manufacturing arm of the Quotient Group. Alba has a distinguished record of developing and manufacturing innovative transfusion diagnostics for Quotient and other major transfusion diagnostics groups worldwide. For more details about the full range of products offered by Alba and Quotient outside of the USA, please visit our websitewww.albabioscience.co.uk.

Based in the USA, Quotient Biodiagnostics, Inc. (the Group’s North American sales and marketing business) provides the US blood banking community with trusted transfusion diagnostics products manufactured over many years by Alba. For more details about the full range of products offered by Quotient in the United States of America, please visit our website www.quotientbd.com.

About Galen Partners
Galen Partners is a leading healthcare venture capital investment firm. The firm focuses on growth equity investments in healthcare technology and services, medical products, and specialty pharmaceutical companies. With nearly $1 billion under management, raised through five funds, Galen has helped build more than 70 companies since our founding in 1990. The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams to build healthcare market leaders. For more information, please visit Galen’s web site atwww.galen.com.

InTouch Health Receives $6 Million Investment from iRobot Corp.

InTouch Health, Inc. 
Medical Devices & Technology

Update: Wednesday, 01 February 2012

Santa Barbara, CA, February 1, 2012 – InTouch Technologies, Inc. (dba. InTouch Health), a leading provider of acute healthcare remote presence solutions, announced today that iRobot Corp., a leader in delivering robot technology-based solutions, has made a $6 million investment in the Company.

InTouch Health and iRobot have a joint development and licensing agreement, formalized in July 2011, to explore opportunities for healthcare applications of robotic technology by uniting complementary expertise and technologies across each company’s intellectual property portfolio.  InTouch Health’s ten years of experience in robotic telemedicine solutions coupled with iRobot’s expertise in robot navigation, mobility and manipulation can prove to be a potent combination in developing purpose-built robots for the healthcare industry. This collaboration will allow InTouch Health to advance its healthcare-centric robotic platform to a new level of mobility and utility, which will allow for even greater ease of use by clinicians.

“As evident from the demonstrations of its Ava robotic platform, iRobot is the industry leader in robot navigation, mobility and manipulation,” said Yulun Wang, Chairman and CEO of InTouch Health. “Working together, InTouch Health and iRobot will pioneer superior remote presence in healthcare settings, providing anytime/anywhere patient care in hospital ED’s, ICU’s, patient wards, and operating and procedure rooms.”

“With over 400 hospitals in the U.S. and around the world utilizing its remote presence products, InTouch Health is in a very unique position in the healthcare field with its FDA-cleared telemedicine devices,” said Colin Angle, Chairman and CEO of iRobot.  “iRobot’s investment in InTouch Health will further align these two leaders, creating a best of breed partnership that will develop robots for remote presence healthcare and assistive technologies for the elderly.”

About InTouch Health
InTouch Health provides comprehensive telemedicine solutions and expertise that enable physicians to perform real-time consults with patients.  Through a single portal, physicians can access InTouch Health’s purpose-built, FDA-cleared remote presence (“RP”) devices to provide care anywhere across the healthcare continuum: EDs, ICUs, procedure rooms, patient wards, clinics, ambulances, and homes.  The InTouch Health Remote Presence telemedicine network is powered through its SureCONNECT® cloud-based infrastructure providing unparalleled connection quality and reliability, interoperability, workflow imaging and documentation, and service and support.  Wherever access to medical expertise is limited, InTouch Health's Remote Presence telemedicine solutions can effectively extend the physician's reach to manage patient care, thereby removing critical time and distance barriers.

The Company has more than 400 hospital locations on six continents enrolled in its Remote Presence network for the delivery of telemedicine services such as stroke, critical care, cardiology, trauma, pediatrics, neonatology, mental health, language translation, clinical education and surgical/procedure mentoring.  For more information about InTouch Health, please visit www.intouchhealth.com.

About iRobot Corp.
iRobot designs and builds robots that make a difference. The company’s home robots help people find smarter ways to clean, and its government and industrial robots protect those in harm’s way. iRobot’s consumer and military robots feature iRobot Aware® robot intelligence systems, proprietary technology incorporating advanced concepts in navigation, mobility, manipulation and artificial intelligence. For more information about iRobot, please visit www.irobot.com.

Contacts:
 
Roselie Wright           
Marketing Communications
InTouch Health
(805)562-8686            
rwright@intouchhealth.com   


Mathew Lloyd
Media Relations
iRobot Corp.
(781)430-3720
mlloyd@irobot.com